Development and Evaluation of Matrix Type Transdermal Patches of Torasemide
TDDS manufacture has numerous benefits over other routes like oral delivery. It avoids limitations linked with g.i.t. absorption, enzyme effect, interaction with drug and food. This route is suitable when patient is suffering from vomiting and diarrhea. Torasemide is a loop diuretic; it comes under category of sulfonyl urea. It is prescribed in the treatment of edema, CHF, and hypertension. Whenever it is used by oral route, it is associated with many side effects like vomiting, nausea, anorexia, and increased appetite. All transdermal patches were transparent and free from any particle. Release profile of twelve batches of Torasemide was done by the means of Franz cell for 7 hrs. Maximum release was shown by MTP6 (71.28±0.19) and least in formulations of batch code MTP7(24.47±0.04). In-vitro release data were plotted in 2 different models i.e. first and Korsemeyer peppas. It was observed that release was governed by the diffusion process. On basis of different properties MTP1 batch was found to be optimum. Study concludes that by the means of patches Torasemide can be administered efficiently.
Keywords: Torasemide, transdermal patches, HPMC, in-vitro release, stability studies, TDDS.
2. Kusum DV, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride, Drug Dev. Ind. Pharm. 2003; 29:495–503.
3. Limpongsa E, Umprayn K. Preparation and evaluation of diltiazem hydrochloride diffusioncontrolled transdermal delivery system. AAPS PharmSciTech. 2008; 9(2):464-70.
4. Sakellariou P, Rowe RC, White EFT. An evaluation of the interaction and plasticizing efficiency of the polyethylene glycols in ethyl cellulose and hydroxypropyl methylcellulose films using the torsional braid pendulum. Int. J.Pharm.1986; 31:55–64.
5. Costa P, Ferreria DC, Morgado R, Sousa Lobo JM. Design and evaluation of a lorazepam transdermal delivery system, Drug Dev Ind Pharm. 1997; 23:939-944.
6. Dimas DA, Dalles PP, Rekkas DD, Choulis NH. Effect of several factors on the mechanical properties of pressure sensitive adhesives used in transdermal therapeutic systems, AAPS PharmSciTech. 2000; 1:E16.
7. Gabiga H, Cal K, Janicki S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system, Int J Pharm. 2000; 199: 1-6.
8. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International journal of pharmaceutics. 2018; 536(1):95-107.
9. Elsaied EH, Dawaba HM, Ibrahim EA, Afouna MI. Investigation of proniosomes gel as a promising carrier for transdermal delivery of Glimepiride. Universal Journal of Pharmaceutical Research 2016; 1(2):1-10.
10. Izumoto T, Aioi A, Uenoyana S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch and physicochemical properties, Chem Pharm Bull (Tokyo) 1992; 40:456-458.
11. Gaur KP, Mishra S, Purohit S and Dave K: Transdermal delivery System: A review. Asian journal of Pharmaceutical and Clinical Research 2009; 2(1):14-20.
12. Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG. "Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis". J Cardiovasc Med (Hagerstown). 2019; 20(6):379–388.
13. Wargo KA, Banta WM (November 2009). "A comprehensive review of the loop diuretics: should furosemide be first line?". Ann Pharmacother. 43(11):1836–47.
14. Dunn CJ, Fitton A, Brogden RN. "Torasemide. An update of its pharmacological properties and therapeutic efficacy". Drugs. 1995; 49 (1):121–42.
15. Francis DJE. Development and evaluation of matrix type transdermal patches of pioglitazone hydrochloride. Universal Journal of Pharmaceutical Research 2016; 1(1):17-20.
16. Chauhan N, Kumar K, Pant NC. An updated review on transfersomes: a novel vesicular system for transdermal drug delivery. Universal Journal of Pharmaceutical Research 2017; 2(4):42-45.
17. Arunachalam A, Karthikeyan, Vinay Kumar D, Prathap M, Sethuraman S, Ashutosh Kumar S and Manidipa S: Transdermal Drug Delivery System: A review. Current Pharma Research 2010; 1(1):70-81.
18. Amnuaikit C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use, Int. J. Pharm. 2005; 289:167– 178.
19. Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of Eudragit: design and in-vitro and in vivo evaluation. Drug Dev. Ind. Pharm. 2000; 26:471–476.
20. Chioma ED. Formulation and evaluation of etodolac niosomes by modified ether injection technique. Universal Journal of Pharmaceutical Research 2016; 1(1):1-4.
21. Durriya Hashmat, Muhammad Harris ShoaibID*, Fatima Ramzan Ali, Fahad Siddiqui. Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers. PLOS ONE February 27, 2020
22. B Raja Narender. Formulation and Evaluation of Physostigmine-Transdermal Patch. World Journal of Current Med and Pharm Research., Vol-II, Iss-II, 125-132.
23. Umar S, Onyekachi MK. Development and evaluation of transdermal gel of Lornoxicam. Universal Journal of Pharmaceutical Research 2017; 2(1):15-18.
24. Baghel S, Naved T, Parvez N. Formulation and development of transdermal drug delivery system of ethinylestradiol and testosterone: in vitro evaluation. Int J App Pharm, 2019; 11(1):55-60.
25. Ifrah Jafri• Muhammad Harris Shoaib1 • Rabia Ismail Yousuf1 • Fatima Ramzan Ali. Effect of permeation enhancers on in vitro release and transdermal delivery of lamotrigine from Eudragit®RS100 polymer matrix type drug in adhesive patches. Progress in Biomaterials 2019; 8:91–100.
26. Kharia A, Gilhotra R, Singhai AK. Formulation and evaluation of transdermal patch for treatment of inflammation. International Journal of Pharmaceutical Sciences and Research. 2019; Vol. 10(5):2375-2384.
27. Fatima AA, Chukwuka UK. Development and in-vitro evaluation of matrix-type transdermal patches of losartan potassium. Universal Journal of Pharmaceutical Research 2017; 2(2):16-20.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).